GW Pharma (GWPH) Tops Q1 EPS by 83c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
GW Pharmaceuticals plc Reports First Quarter 2020 Financial Results and Operational Progress
May 11, 2020 4:00 PM EDT- Total revenue of $120.6 million - - Total Epidiolex® net product sales of $116.1 million - - Conference call today at 4:30 p.m. EDT
LONDON and CARLSBAD, Calif., May 11, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announces financial results for the first quarter ended March 31, 2020.
In the first quarter of 2020, we have seen continued strength of the Epidiolex brand in both the U.S. and Europe and... More
